Can AbbVie Beat Pfizer in the Atopic Dermatitis Market?

·3 min read

Both AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) recently picked up regulatory approvals for JAK inhibitors for treating atopic dermatitis. In this Motley Fool Live video recorded on Jan. 19, Motley Fool contributors Keith Speights and Brian Orelli discuss whether AbbVie is likely to beat Pfizer in this large market.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting